Should you start a GLP-1? What TikTok gets right and wrong

What's this video probably claiming?

Based on the caption and category context, @asyiaandrews appears to be at a decision point about starting a GLP-1 receptor agonist, likely semaglutide or tirzepatide, and is either soliciting advice from her audience or walking through her own deliberation publicly. This is a pattern we see constantly on weight-loss TikTok: a creator positions themselves as relatable, uncertain, and open to crowd-sourced input. That framing is not inherently harmful, but it creates a feedback loop where anecdote replaces clinical guidance. The comment sections on these videos tend to fill with personal success stories, dose recommendations from strangers, and comparisons between branded products like Ozempic or Wegovy and compounded versions. Without the transcript, we cannot confirm exactly what claims she makes, but the category tag and caption structure strongly suggest this is a GLP-1 consideration or "should I try it" video. Phase 2 will verify this against the actual audio.

What does the science actually show?

GLP-1 receptor agonists have some of the most strong weight-loss trial data we have seen in pharmacology. The SURMOUNT-1 trial (Jastreboff et al., 2022, New England Journal of Medicine) showed tirzepatide at 15mg produced mean body weight reduction of 20.9% over 72 weeks in adults with obesity but not diabetes. The STEP 1 trial (Wilding et al., 2021, NEJM) showed semaglutide 2.4mg weekly produced 14.9% mean weight loss over 68 weeks. These are not trivial numbers. But they come with important asterisks: effects are dose-dependent, side effect profiles are real, and roughly 10-15% of participants in these trials discontinued due to gastrointestinal adverse events including nausea, vomiting, and diarrhea. Weight regain after stopping is also documented, with Wilding et al. (2022, Diabetes, Obesity and Metabolism) showing participants regained two-thirds of lost weight within a year of discontinuation.

Where does the social media noise diverge from clinical reality?

TikTok's GLP-1 discourse has a few consistent distortions. First, it underplays the importance of patient selection. These medications are FDA-approved for adults with a BMI of 30 or higher, or 27 or higher with at least one weight-related comorbidity. They are not lifestyle accessories. Second, comment-section culture normalizes dose-sharing and off-label stacking advice that has no clinical basis. Third, creators frequently blur the line between compounded semaglutide and brand-name products like Wegovy or Ozempic. Compounded versions are not FDA-approved, and the FDA has explicitly warned that compounded semaglutide products cannot be considered equivalent to the approved formulations. That is not a technicality. It affects what you actually know about purity, potency, and safety. Fourth, the "I'm thinking about it" framing invites audience members to act as informal prescribers, which is how people end up with doses that were not designed for their body weight or metabolic profile.

What should you actually know?

If you are genuinely considering a GLP-1, the conversation belongs with a licensed clinician who can review your cardiovascular history, thyroid status, and any personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2, both of which are contraindications. The FDA label for semaglutide carries a black box warning for these conditions. Beyond contraindications, the evidence is clear that GLP-1 agonists work best alongside structured behavioral support. A 2023 analysis by Rubino et al. in Obesity showed that medication alone without lifestyle intervention produced meaningfully smaller and less sustained outcomes. The exciting efficacy numbers from SURMOUNT and STEP trials came from controlled settings with dietary and activity counseling included. TikTok cannot replicate that context, and a creator's positive experience, however genuine, does not transfer to your individual physiology.